Ivabradín Sandoz

Ivabradine, the active ingredient in Ivabradín Sandoz, is a If channel inhibitor presented as an oral formulation for oral use. It lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradín Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current, making it useful in conditions where heart‑rate reduction improves outcomes. - Chronic stable angina: reduces frequency of angina episodes and improves exercise tolerance. - Heart failure with reduced ejection fraction (NYHA class II–III): lowers resting heart rate, decreasing hospitalizations and symptom burden. - Elevated resting heart rate in chronic heart failure: contributes to better functional capacity when added to standard therapy.

Ivabradine may be associated with several adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: excessively low heart rate. - Headache. - Dizziness.

Serious or Rare Side Effects: - Symptomatic atrial fibrillation. - Severe hypotension. - Vision loss (retinal dysfunction) – rare.

When prescribing Ivabrín Sandoz, clinicians should consider the following precautions. - Cardiovascular assessment: evaluate baseline heart rate and rhythm before initiation. - Concomitant β‑blocker therapy: avoid excessive heart‑rate lowering when combined with other rate‑controlling drugs. - Hepatic impairment: use with caution in patients with moderate liver dysfunction. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Visual monitoring: advise patients to report any changes in vision promptly. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Ivabrín Sandoz can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine plasma levels, raising risk of bradycardia. - Concomitant use with other heart‑rate‑lowering agents (e.g., digoxin, diltiazem, verapamil): can cause excessive bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may require dose adjustment. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): can reduce ivabradine exposure, diminishing efficacy. - Antihypertensive agents: monitor blood pressure for additive effects.